Nailfold videocapillaroscopic patterns and serum autoantibodies in systemic sclerosis.

BACKGROUND Microvascular lesions are a predominant feature in systemic sclerosis (SSc) and seem to play a central pathogenetic role. Recently, we graded scleroderma microangiopathy by nailfold videocapillaroscopy (NVC) into three NVC patterns (early, active and late). The aim of the present study was to confirm, in a larger number of SSc patients, the presence of three patterns of microvascular damage, and to detect any possible relationship between these patterns and both specific serum autoantibodies and the subsets of cutaneous involvement. METHODS Two hundred and forty-one consecutive patients (227 women and 14 men) affected by SSc were recruited. One hundred and forty-eight patients were affected by limited cutaneous SSc (lSSc) and 93 patients by diffuse cutaneous SSc (dSSc). The ages at onset of Raynaud's phenomenon (RP) and SSc, the durations of RP and SSc, ANA and antitopoisomerase I (anti-Scl70) and anticentromere (ACA) antibodies were investigated in all patients. The SSc patients were subdivided on the basis of the NVC pattern into three groups. RESULTS A statistically significant correlation was found between the NVC patterns and the durations of both RP and SSc (P<0.001). Enlarged and giant capillaries, together with haemorrhages, constituted the earliest NVC finding in SSc (early NVC pattern). These abnormalities were mostly expressed in the active NVC pattern. Loss of capillaries, ramified capillaries and vascular architectural disorganization were increased in the late NVC pattern. Age and the duration of both RP and SSc were lower in 24 patients complaining of RP alone. Anti-Scl70 antibodies were statistically less frequent in the early vs both the active and the late NVC pattern, whereas no significant correlation was found between the presence of anti-Scl70 antibodies and the duration of either RP or SSc. ACA positivity was more frequent in patients with longer RP duration. Patients with lSSc had shorter SSc duration and showed the early or active NVC pattern more frequently. Conversely, patients with dSSc showed longer disease duration and mostly showed the late NVC pattern. CONCLUSIONS NVC is an appropriate tool for differential diagnosis between primary and secondary RP through the clear recognition of the early NVC scleroderma pattern. This study confirms, in a large number of SSc patients, the existence of three distinct NVC patterns that might reflect the evolution of SSc microangiopathy. The presence of anti-Scl70 antibodies seems be related to earlier expression of the active and late NVC patterns of SSc microvascular damage. The presence of ACA seems to be related to delayed expression of the late NVC pattern.

[1]  T Moore,et al.  Quantitation of microcirculatory abnormalities in patients with primary Raynaud's phenomenon and systemic sclerosis by video capillaroscopy. , 2000, Rheumatology.

[2]  R. Fleischmajer,et al.  Immunopathogenesis of scleroderma--evolving concepts. , 2001, The Mount Sinai journal of medicine, New York.

[3]  A. Silman,et al.  A disease severity scale for systemic sclerosis: development and testing. , 1999, The Journal of rheumatology.

[4]  C. Black Systemic sclerosis 'state of the art' 1995. , 1995, Scandinavian journal of rheumatology.

[5]  R. Scorza,et al.  Lymphocyte-endothelium interaction in systemic sclerosis and Raynaud's phenomenon. , 2001, Clinical and experimental rheumatology.

[6]  T. Medsger,et al.  Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. , 1988, The Journal of rheumatology.

[7]  H. Maricq,et al.  A prospective study of Raynaud phenomenon and early connective tissue disease. A five-year report. , 1982, The American journal of medicine.

[8]  M. Jayson,et al.  Mechanisms of endothelial cell damage in systemic sclerosis and Raynaud's phenomenon. , 1993, The Journal of rheumatology.

[9]  E. Atra,et al.  Panoramic nailfold capillaroscopy: a new reading method and normal range. , 1990, Seminars in arthritis and rheumatism.

[10]  E Michoud,et al.  Digitized nailfold capillaroscopy. , 1994, VASA. Zeitschrift fur Gefasskrankheiten.

[11]  A. Silman,et al.  European multicentre study to define disease activity criteria for systemic sclerosis.* II. Identification of disease activity variables and development of preliminary activity indexes , 2001, Annals of the rheumatic diseases.

[12]  M. Cutolo,et al.  Long-term treatment of patients affected by systemic sclerosis with cyclosporin A. , 2001, Rheumatology.

[13]  J. Pearson,et al.  The endothelium: its role in scleroderma. , 1991, Annals of the rheumatic diseases.

[14]  Maricq Hr,et al.  Microvasculature in systemic sclerosis. , 1990 .

[15]  Richard W. Martin,et al.  Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. , 2002, Arthritis and rheumatism.

[16]  Maurizio Cutolo,et al.  Raynaud's phenomenon and the role of capillaroscopy. , 2003, Arthritis and rheumatism.

[17]  M. Hasegawa,et al.  Clinical significance of anti-topoisomerase I antibody levels determined by ELISA in systemic sclerosis. , 2001, Rheumatology.

[18]  P. Priollet,et al.  How to classify Raynaud's phenomenon. Long-term follow-up study of 73 cases. , 1987, The American journal of medicine.

[19]  N Houtman,et al.  Nailfold videocapillaroscopy assessment of microvascular damage in systemic sclerosis. , 2000, The Journal of rheumatology.

[20]  E. Tan,et al.  Microvascular abnormalities as possible predictors of disease subsets in Raynaud phenomenon and early connective tissue disease. , 1983, Clinical and experimental rheumatology.

[21]  R. Abbate,et al.  High prevalence of polymorphisms of angiotensin-converting enzyme (I/D) and endothelial nitric oxide synthase (Glu298Asp) in patients with systemic sclerosis. , 2002, The American journal of medicine.

[22]  M. Conforti,et al.  Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers , 2002, Arthritis research.

[23]  M. Ahern,et al.  A study of scleroderma in South Australia: prevalence, subset characteristics and nailfold capillaroscopy. , 1995, Australian and New Zealand journal of medicine.

[24]  H. Anders,et al.  Differentiation between primary and secondary Raynaud's phenomenon: a prospective study comparing nailfold capillaroscopy using an ophthalmoscope or stereomicroscope , 2001, Annals of the rheumatic diseases.

[25]  T. Medsger,et al.  Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. , 1988, Arthritis and rheumatism.

[26]  M. Lovy,et al.  Relationship between nailfold capillary abnormalities and organ involvement in systemic sclerosis. , 1985, Arthritis and rheumatism.

[27]  T. Medsger,et al.  Evolution of primary Raynaud's phenomenon (Raynaud's disease) to connective tissue disease. , 1985, Arthritis and rheumatism.

[28]  D. Blockmans,et al.  Predictive value of nailfold capillaroscopy in the diagnosis of connective tissue diseases , 1996, Clinical Rheumatology.

[29]  M. Kuwana,et al.  Clinical and prognostic associations based on serum antinuclear antibodies in Japanese patients with systemic sclerosis. , 1994, Arthritis and rheumatism.

[30]  P. von Wichert,et al.  Intravital microscopy and capillaroscopically guided nail fold biopsy in scleroderma. , 1996, Annals of the rheumatic diseases.

[31]  A. Masi Preliminary criteria for the classification of systemic sclerosis (scleroderma). , 1980, Bulletin on the rheumatic diseases.

[32]  A. Gelber,et al.  Recognition of Granzyme B-generated autoantigen fragments in scleroderma patients with ischemic digital loss. , 2002, Arthritis and rheumatism.

[33]  H. Maricq,et al.  Widefield capillary microscopy. technique and rating scale for abnormalities seen in scleroderma and related disorders , 1981 .

[34]  E Mannarino,et al.  Nailfold Capillaroscopy in the Screening and Diagnosis of Raynaud's Phenomenon , 1994, Angiology.

[35]  D. Abraham,et al.  Transforming growth factor-&bgr; and connective tissue growth factor: key cytokines in scleroderma pathogenesis , 2001, Current opinion in rheumatology.

[36]  W. Earnshaw,et al.  Clinical associations of anticentromere antibodies and antibodies to topoisomerase I. A study of 355 patients. , 1988, Arthritis and rheumatism.

[37]  M. Alavi,et al.  Coexistence of antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis , 2002, Annals of the rheumatic diseases.

[38]  J. Raynauld,et al.  Updating the American College of Rheumatology preliminary classification criteria for systemic sclerosis: addition of severe nailfold capillaroscopy abnormalities markedly increases the sensitivity for limited scleroderma. , 2001, Arthritis and rheumatism.

[39]  J. F. Wolfe,et al.  Diagnostic potential of in vivo capillary microscopy in scleroderma and related disorders. , 1980, Arthritis and rheumatism.

[40]  E F Ring,et al.  Quantitative nailfold capillaroscopy findings in a population with connective tissue disease and in normal healthy controls. , 1996, Annals of the rheumatic diseases.

[41]  Y. Okano,et al.  Antinuclear antibody in systemic sclerosis (scleroderma). , 1996, Rheumatic diseases clinics of North America.

[42]  Jane Worthington,et al.  Genetic epidemiology: Systemic sclerosis , 2002, Arthritis Research & Therapy.

[43]  S. Rantapää-Dahlqvist,et al.  Assessment of vascular function in systemic sclerosis: indications of the development of nitrate tolerance as a result of enhanced endothelial nitric oxide production. , 2002, Arthritis and rheumatism.

[44]  E. Leroy,et al.  Raynaud's phenomenon and scleroderma. , 1981, Comprehensive therapy.

[45]  T. Medsger,et al.  Criteria for the classification of early systemic sclerosis. , 2001, The Journal of rheumatology.

[46]  E. Sato,et al.  Scleroderma-like nailfold capillaroscopic abnormalities are associated with anti-U1-RNP antibodies and Raynaud's phenomenon in SLE patients , 2002, Lupus.

[47]  A. Sulli,et al.  Lack of correlation between gastric Helicobacter pylori infection and primary or secondary Raynaud's phenomenon in patients with systemic sclerosis. , 2000, The Journal of rheumatology.

[48]  M. Cerinic,et al.  Raynaud's phenomenon and scleroderma. Dysregulated neuroendothelial control of vascular tone. , 1995, Arthritis and rheumatism.

[49]  C. Black,et al.  The aetiopathogenesis of systemic sclerosis , 1993, Journal of internal medicine.

[50]  Y. Shoenfeld,et al.  Anti-Endothelial Cell Antibodies (AECA) in Systemic Sclerosis - Increased Sensitivity using Different Endothelial Cell Substrates and Association with Other Autoantibodies , 2001, Autoimmunity.

[51]  R M Silver,et al.  Association between fluorescent antinuclear antibodies, capillary patterns, and clinical features in scleroderma spectrum disorders. , 1984, The American journal of medicine.

[52]  E. Hess,et al.  Prospective study of the evolution of Raynaud's phenomenon. , 1988, The American journal of medicine.

[53]  P. Vitali,et al.  Evidence of cerebral hypoperfusion in scleroderma patients. , 2000, Rheumatology.